Astellas Pharma Inc. delivered solid FY2025 results underpinned by health care sector tailwinds, disciplined operational execution, and a durable business model. Revenue reached Y2060.6B, growing approximately 10% year-on-year, driven by volume growth, pricing power, and expanding product/service mi
Access the complete analysis, financial model, price target breakdown, and risk factors.
Read Full Report →2 free reads per day · No credit card required